User:Nixonchan1/sandbox

Barricade Therapeutics, Corp. is a privately held Biotech company based in Houston & Dallas, TX and it was founded based on discovery and advancement of novel first in class small molecules, by integrating complex molecule synthesis, chemistry, and molecular pharmacology with targeted therapeutic approaches in cancer biology. The company focuses on the development of uniquely innovative targeted drugs for the treatment of patients with cancer and it is currently at the nonclinical stage of the development.

History
Barricade Therapeutics is co-founded by a team of scientists and management experts in 2017. The founding scientists include Jef K. De Brabander, PhD, Jerry W. Shay, PhD and Deepak Nijhawan MD, PhD. The founding management team include Frank Perabo, MD PhD, Neil Thapar, PharmD, RPh and Vlad Vitoc, MD, MBA.

Nobel Drugs
Jef De Brabander, Ph.D. and Jerry W. Shay, Ph.D., at the University of Texas Southwestern, Medical Center, Dallas, TX. discovered the two nobel drugs, namely TASIN and THIO.

TASIN
TASIN is a unique, first-in-class compound with a mechanism of action targeting truncated APC (adenomatous polyposis coli), one of the earliest and most critical mutations occurring in colorectal cancer (CRC). Truncated APC has a dominant role in CRC initiation and cancer progression and is expressed in >80% of those CRC tumors. Extensive preclinical work on TASIN demonstrates highly potent and selective targeting of truncated APC, resulting in significant inhibition of CRC tumor growth with no apparent toxicity to normal cells.

THIO
THIO specifically targets tumorcell DNA and causes damage to DNA ends (telomeres), resulting in the selective death of tumor cells. This approach targets an almost universal driver of tumor growth and is supported by extensive preclinical work showing very significant antitumor activity across a broad range of tumors refractory to I/O-, BRAF-, EGFR-targeted therapies, as well as chemotherapy. Currently, patients failing these treatments have a poor prognosis and few alternative treatment options. THIO utilizes a novel mechanism of action, which successfully circumvents those resistance mechanisms, without relevant toxicity.

Development Pipline
Both TASIN and THIO are currently at the non-clinical development stage.

Funding
Seed funding of xxx amount was received